Peter Travers is a serial entrepreneur and marketing strategist with a background in healthcare communications, consumer insights, and franchise development. He has founded multiple companies, including a medical patient education firm whose training materials were adopted by over 3,000 hospitals nationwide and viewed by more than one million patients annually via closed-circuit television systems.

As President of Comprehensive Loyalty, Inc., Peter has advised CEOs of midsize franchise companies on growth strategy, overseeing more than 400 predictive site selection studies and over 200,000 consumer surveys. He has delivered marketing support to more than 50 companies and spoken at numerous industry events. Since 2015, he has served as CEO of LifeBridge Innovations, where he is also a named inventor on the U.S. patent for the LB10000 device.

Peter holds a BA in Communications from the University of Central Florida.

Ken Watkins is an electrical engineer and product development leader with over 40 years of experience driving innovation in high-tech systems across defense and medical technology. He currently leads the development of the LB10000 system and ongoing advancements in Tumor Treating Fields at LifeBridge.

Previously, Ken served as Electrical Engineering Manager at Northrop Grumman, where he oversaw a team of 30 engineers. Earlier in his career, he held top-secret clearance at Gulton Industries while working on the Trident Missile program. He is also the author of a technical guide on converting gas-powered vehicles to electric.

Ken holds a BS and MS in Electrical and Electronics Engineering from the University of New Mexico.

Dr. Ze’ev Bomzon is a multidisciplinary scientist and R&D leader with experience spanning optics, metrology, electromagnetics, and cell biology across academia, defense, semiconductors, and medical devices. He served as Head of Science at Novocure from 2014 to 2021, where he conceptualized and led a physics and algorithms team focused on the biophysics of Tumor Treating Fields. Under his leadership, the team grew to over 15 physicists and engineers and contributed to foundational research and multiple TTFields patents.

Since 2021, Dr. Bomzon has transitioned to early-stage innovation, leading the development of novel medical technologies. At Votis, he advanced an electro-optic diagnostic device for peripheral arterial disease, and at AIVF, he heads a team of engineers and scientists building AI tools for IVF clinics. He currently advises LifeBridge on FDA-related simulations, device validation, and scientific publications supporting Adaptive Tumor Treating Fields.

Dr. Bomzon holds a BA in Mathematics and Physics, an MSc in Optical Engineering, and a PhD in Bioengineering and Civil Engineering from the Technion – Israel Institute of Technology.

Dr. Lee Zehngebot is a clinical researcher and oncologist with extensive experience leading early- and late-stage cancer trials across academic and hospital settings. Since 2007, he has served as Director of Clinical Research at the Florida Hospital Cancer Institute in Orlando, where he has acted as Principal Investigator and Co-Investigator on numerous studies.

Dr. Zehngebot helped the institute earn a Clinical Trials Participation National Award from ASCO in 2008, and his research has been published in top-tier journals including the Journal of Clinical Oncology, Cancer, and Annals of Oncology. He has been recognized regionally as one of the Best Doctors in America.

Dr. Zehngebot holds an MD from the University of Pennsylvania School of Medicine and a BS from Union College.

Scott Krywick is a technologist and engineer with nearly 30 years of experience spanning commercial and defense applications in image processing, command and control systems, and embedded computing. He has held technical roles at Martin Marietta, Lockheed, Coleman Research, Teranex, and Northrop Grumman, contributing to projects ranging from space shuttle safety and land mine detection to high-definition video systems and precision-guided munitions.

Scott’s work has included detecting weld flaws in shuttle fuel tanks, identifying aircraft from infrared video, and integrating lasers with celestial tracking for targeting systems. He received a technical Emmy award for his contributions to high-definition video imaging and currently supports the LifeBridge Innovations development team.

Scott holds a BS in Electrical Engineering from the University of Central Florida.

Mike Winegar is a regulatory strategist and educator with over 30 years of experience guiding medical device development and FDA engagement. He has held senior roles at Medtronic and Boston Scientific and led the successful clearance of more than 50 devices. Mike serves as the Regulatory Science Program Lead at the University of St. Thomas and is Principal at Winegar Consulting. 

Since 2019, he has directed regulatory strategy for LifeBridge, overseeing FDA interactions, clinical trial approvals, design control documentation, and compliance across engineering teams. 

Mike holds a BS in Microbiology from the University of Minnesota.

Mike Black is a business leader and operator with two decades of executive experience in the medical device industry, including CEO, CFO, and COO roles across early-stage and growth-stage companies. He led an innovative device startup from early commercialization through a successful strategic exit and previously held executive positions at Advanced Circulatory Systems, acquired by ZOLL.

Mike currently advises early-stage medtech companies, serves on the board of Visura Technologies, and supports an established angel investor network. He began his career as a financial auditor and consultant at Deloitte.

Mike holds an MBA from the University of Minnesota Carlton School of Management and a BS in Accounting from the University of Iowa.

Michael Hoyos is an investor and operator with a focus on frontier therapeutics and a background in venture capital, private equity, and consulting. He previously worked at McKinsey & Company, where he led engagements for Fortune 500 companies and nonprofit clients across the firm’s life sciences, healthcare, and social sector practices.

Before McKinsey, Michael co-founded an early-stage venture firm investing in novel CNS therapeutics to address mental health, addiction, and pain. He also led an advisory firm supporting ultra-high-net-worth families in managing direct private equity portfolios exceeding $100 million. He began his career at JPMorgan.

Michael holds an MBA from the University of Chicago Booth School of Business and a BS in Economics from the Wharton School at the University of Pennsylvania.

Matthew Travers is a software engineer and medical simulation specialist focused on advancing personalized cancer treatment through computational modeling. He leads medical simulations and programming at LifeBridge Innovations, where he develops patient-specific simulations using tools like Sim4Life to optimize Tumor Treating Fields therapy.

His work includes integrating imaging data into digital phantoms to design precise electromagnetic field configurations for tumor targeting. Matthew is also a co-inventor on a U.S. patent for a multi-tumor TTF treatment system, reflecting his contributions to next-generation oncology technologies. 

Matthew holds a BA in Computer Science from Rollins College. 

Maggie Scheuermann is a biomedical engineer and project management consultant with expertise across the full lifecycle of medical device development. She has led projects spanning Class I to Class III devices, guiding them from early concept and design through manufacturing and post-market surveillance. 

With experience supporting both startups and mid-sized enterprises, Maggie brings a versatile and adaptive approach to medical device innovation. Her ability to navigate the regulatory and operational challenges of companies at different stages has made her a trusted partner in bringing novel technologies to market. 

Maggie holds both a BS and a MS in biomedical engineering. 

Jim Murray is a medical device executive and operations leader with over 30 years of experience spanning product development, quality management, and commercialization of Class III devices and combination products. He entered the medtech industry in 1994 following earlier roles in electronics and manufacturing and has since contributed to FDA-regulated programs across implantables, drug-device combinations, and diagnostic tools. 

Jim has held leadership roles at St. Jude Medical, superDimension, Angioslide, Cardiovascular Systems, Rebiotix, and several early-stage ventures including Mardil Medical, AUM Cardiovascular, and Sunshine Heart. As a consultant, he has supported medtech startups such as Peytant Solutions, AdrenaCard, and HistoSonics, guiding IDE, PMA, IND, and NDA submissions, supply chain development, and quality system implementation. He currently serves as Principal at Stillwater Medtech Consulting. 

Jim holds an MS in Management of Technology from the University of Minnesota’s Technological Leadership Institute, a BS in Mechanical Engineering from the University of Minnesota Institute of Technology, and an AS in Electronic Technology from St. Paul Technical College. 

Jim LaBate is an experienced investor and financial strategist with over four decades in public and private markets. He spent more than 30 years at Merrill Lynch and Morgan Stanley, where he managed a $300 million equity and debt portfolio using a deep-value investment philosophy. 

In addition to his public market work, Jim has invested in, managed, and exited multiple private companies across sectors including technology, entertainment, security, agriculture, and healthcare. His background also includes significant experience in real estate development and structured finance.  

An engaged civic leader, Jim has served as Chairman of the Association for Corporate Growth, Community Foundation of Broward, Broward College Foundation, and Bonnet House Museum & Gardens. He has also held board positions with the Boys & Girls Clubs, YMCA, and the Broward Center for the Performing Arts. 

Jim holds a BS in Business Administration from Indiana University of Pennsylvania and has completed graduate coursework at Geneva College, Florida Atlantic University, and the University of Pittsburgh. 

Ping Yeh is a biotechnology entrepreneur and technology commercialization leader with a multidisciplinary background spanning life sciences, nanotechnology, and enterprise storage systems. He co-founded StemoniX, Inc. in 2014 and served as its CEO and Board Member through its 2021 merger with public company Vyant Bio (formerly Cancer Genetics). 

Before entering biotech, Ping led key innovation programs in the tech industry, including the launch of Seagate’s first solid state drive, global flash development partnerships with Samsung, and OS development for Dell’s enterprise storage systems. He is known for applying a systems-level approach across diverse sectors to drive innovation and successful commercialization. 

He serves on the boards of Medical Alley, the UC San Diego Alumni Association, and Oncodea, a cancer diagnostics company. 

Ping holds a BS and MS in Mechanical Engineering with a focus on nanotechnology from the University of California, San Diego, and an MBA in Strategic Management from the University of Minnesota’s Carlson School of Management.